The long-term outcome of patients with polycystic liver disease treated with lanreotide.

来自 EBSCO

阅读量：

作者：

M Chrispijn，F Nevens，TJG Gevers，R Vanslembrouck，MGHV Oijen，W Coudyzer，AL Hoffmann，HM Dekker，RAD Man，LV Keimpema

展开

摘要：

Top of pageIntroduction Materials and Methods Results Discussion Conclusion Acknowledgements References Aliment Pharmacol Ther 2012; 35: 266–274 Summary Background Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume. Aim To establish long-term outcome and safety of lanreotide. Methods This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120mg/month) in PLD. The length of total treatment was 12months. Primary endpoint was relative change in liver volume, as determined by CT-volumetry after 12months of treatment. We offered patients a CT scan 6months after stopping lanreotide. Results A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR 8% to 1%) after 12months of treatment. The greatest effect was observed during the first 6months of treatment (decrease of 4% (IQR 6% to 1%)). Liver volume remained unchanged during the following 6months. We found that liver volume increased by 4% (IQR 0–6%) 6months after end of treatment ( n =22). Conclusions Lanreotide reduces liver volume within the first 6months of treatment and the beneficial effect is maintained in the following 6months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.

展开

关键词：

maca Lepidium meyenii Brassicaceae metabolite NMR chemometrics

DOI：

10.1111/j.1365-2036.2011.04923.x

被引量：

105

年份：

2012